TILS.L Regulatory News (TILS)

10 Dec 2007 16:30

ReGen Therapeutics PLC10 December 2007 ReGen Therapeutics Plc 10 December 2007 REGEN THERAPEUTICS PLC ANNUAL CITY PRESENTATION ReGen Therapeutics Plc ('ReGen' or the "Company") announces that thepresentation for its annual update for City investors has been placed on itswebsite www.regentherapeutics.com . The Company would like to make the followingspecific points: 1. The peptide programme, derived from the original Colostrinin(TM), has presented some interesting compounds for further development to a pre-clinical stage for possible entry into the clinic in 2009. ReGen has selected three candidates, two of which may have a potential utility in Alzheimer's disease and a further candidate for a potential utility in obesity. 2. The 'proof of concept' trial for zolpidem will take place during the first part of 2008 and results will be available during the second half of 2008. Assuming these results are successful the Company will continue with its plans to license the product. 3. The Company is in active discussions in both Europe and Japan with companies interested in licensing/distributing Colostrinin(TM)as a nutraceutical. 4. Preliminary results of a study of Colostrinin(TM)in the treatment of dementia in aging dogs look encouraging. The study has now finished the dosing phase and a preliminary report based on 22/34 subjects shows that Colostrinin(TM)is well tolerated and that '40% of owners felt that there had been signs of improvement' throughout the trial. The dosing phase in a similar study in cats is just completing. Both studies are expected to be fully reported by the end of January 2008. If the preliminary findings are confirmed these results will be discussed in confidence with potential licensees. 5. The Company has sales of Colostrinin(TM)as 'CogniSure' through its licensee Metagenics Inc in both the US and Australasia but in view of the importance of these figures will only report on them at the Preliminary and Interim results. For further information: Percy LomaxReGen Therapeutics PlcTel No 020 7153 4920 Andrew MarshallGreycoat CommunicationsTel No 020 7960 6007Mobile 07785 297111 Roland Cornish/Felicity GeidtBeaumont Cornish LimitedTel No 020 7628 3396 This information is provided by RNS The company news service from the London Stock Exchange